Search research articles
Contact Us
Filters
Showing results (221-230 of 293) with videos related to
Page
of 30
Sort By:
NPJ Breast Cancer
|
November 16, 2017
A metastasis biomarker (MetaSite <i>Breast</i>™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer
Joseph A Sparano, Robert Gray, Maja H Oktay, et al.
Breast Cancer Research and Treatment
|
October 21, 2024
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108
Vered Stearns, Anne ONeill, Bryan P Schneider, et al.
Cancer
|
November 2, 2021
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events
Edward H Ip, Santiago Saldana, Kathy D Miller, et al.
Breast Cancer Research and Treatment
|
June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
Yifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 6, 2008
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
Lori J Goldstein, Robert Gray, Sunil Badve, et al.
Breast Cancer Research and Treatment
|
February 2, 2018
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
E Rakovitch, R Gray, F L Baehner, et al.
Breast Cancer Research and Treatment
|
April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2009
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer
Joseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2011
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer
Joseph A Sparano, Lori J Goldstein, Barrett H Childs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2025
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data
Frederick M Howard, Peter A Fasching, Cesar A Santa-Maria, et al.
Page
of 30
Search research articles
Search
Showing results (221-230 of 293) with videos related to
Sort By:
Page
of 30
NPJ Breast Cancer
|
November 16, 2017
A metastasis biomarker (MetaSite <i>Breast</i>™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer
Joseph A Sparano, Robert Gray, Maja H Oktay, et al.
Breast Cancer Research and Treatment
|
October 21, 2024
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108
Vered Stearns, Anne ONeill, Bryan P Schneider, et al.
Cancer
|
November 2, 2021
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events
Edward H Ip, Santiago Saldana, Kathy D Miller, et al.
Breast Cancer Research and Treatment
|
June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
Yifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 6, 2008
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
Lori J Goldstein, Robert Gray, Sunil Badve, et al.
Breast Cancer Research and Treatment
|
February 2, 2018
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
E Rakovitch, R Gray, F L Baehner, et al.
Breast Cancer Research and Treatment
|
April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2009
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer
Joseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2011
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer
Joseph A Sparano, Lori J Goldstein, Barrett H Childs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2025
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data
Frederick M Howard, Peter A Fasching, Cesar A Santa-Maria, et al.
Page
of 30